Clinical trialNCT04625972CompletedPhase 3Interventional

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

SponsorAstraZenecaEnrollment1,131COVID-19

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Myron Levin, MD
AstraZeneca
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

57 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom

Research Site
Bournemouth, United Kingdom
Research Site
Hayle, United Kingdom
Research Site
London, United Kingdom
Research Site
London, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Southampton, United Kingdom

United States

Research Site
Guntersville, Alabama, United States
Research Site
Tempe, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Bakersfield, California, United States
Research Site
Corona, California, United States
Research Site
Garden Grove, California, United States
Research Site
Huntington Beach, California, United States
Research Site
Huntington Park, California, United States
Research Site
Modesto, California, United States
Research Site
Coral Gables, Florida, United States
Research Site
Coral Springs, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami Lakes, Florida, United States
Research Site
Miami Lakes, Florida, United States
Research Site
Miami Springs, Florida, United States
Research Site
Mt. Dora, Florida, United States
Research Site
North Miami, Florida, United States
Research Site
Pembroke Pines, Florida, United States
Research Site
Pompano Beach, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
West Palm Beach, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Buford, Georgia, United States
Research Site
Conyers, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Chicago, Illinois, United States
Research Site
Hazel Crest, Illinois, United States
Research Site
Noblesville, Indiana, United States
Research Site
West Des Moines, Iowa, United States
Research Site
Wichita, Kansas, United States

17 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AZD7442Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 2 Dec 2020
Primary completion: 7 Apr 2021
Completion: 25 Jul 2022
Last update posted: 21 Nov 2023
Registered enrollment: 1,131
Registry id: NCT04625972

Cross-registrations

EU-CTR / CTIS (EudraCT)2020-004719-28

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.